Black Diamond Therapeutics, Inc

Black Diamond Therapeutics, Inc. (www.blackdiamondtherapeutics.com) is a precision oncology medicine company. The Company is focused on the discovery and development of small molecule, MasterKey therapies. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) and HER2. BDTX-1535 is designed as a brain-penetrant small molecule inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. It also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).

• Black Diamond Therapeutics, Inc